B and T Cell Phenotypic Profiles of African HIV-Infected and HIV-Exposed Uninfected Infants: Associations with Antibody Responses to the Pentavalent Rotavirus Vaccine
Overview
Authors
Affiliations
We examined associations between B and T cell phenotypic profiles and antibody responses to the pentavalent rotavirus vaccine (RV5) in perinatally HIV-infected (PHIV) infants on antiretroviral therapy and in HIV-exposed uninfected (PHEU) infants enrolled in International Maternal Pediatric Adolescent AIDS Clinical Trials P1072 study (NCT00880698). Of 17 B and T cell subsets analyzed, PHIV and PHEU differed only in the number of CD4+ T cells and frequency of naive B cells, which were higher in PHEU than in PHIV. In contrast, the B and T cell phenotypic profiles of PHIV and PHEU markedly differed from those of geographically matched contemporary HIV-unexposed infants. The frequency of regulatory T and B cells (Treg, Breg) of PHIV and PHEU displayed two patterns of associations: FOXP3+ CD25+ Treg positively correlated with CD4+ T cell numbers; while TGFβ+ Treg and IL10+ Treg and Breg positively correlated with the frequencies of inflammatory and activated T cells. Moreover, the frequencies of activated and inflammatory T cells of PHIV and PHEU positively correlated with the frequency of immature B cells. Correlations were not affected by HIV status and persisted over time. PHIV and PHEU antibody responses to RV5 positively correlated with CD4+ T cell counts and negatively with the proportion of immature B cells, similarly to what has been previously described in chronic HIV infection. Unique to PHIV and PHEU, anti-RV5 antibodies positively correlated with CD4+/CD8+FOXP3+CD25+% and negatively with CD4+IL10+% Tregs. In conclusion, PHEU shared with PHIV abnormal B and T cell phenotypic profiles. PHIV and PHEU antibody responses to RV5 were modulated by typical HIV-associated immune response modifiers except for the association between CD4+/CD8+FOXP3+CD25+Treg and increased antibody production.
Kelly M, Cunningham C, McFarland E, Giganti M, Lindsey J, Perlowski C Open Forum Infect Dis. 2024; 11(12):ofae679.
PMID: 39610407 PMC: 11604081. DOI: 10.1093/ofid/ofae679.
Saleh Z, Mehdipour F, Ataollahi M, Ali-Hassanzadeh M, Kabelitz D, Kalantar K Curr Microbiol. 2023; 80(9):296.
PMID: 37488238 DOI: 10.1007/s00284-023-03367-0.
Shi P, Wang X, Su M, Meng J, Wang H, Fan W Dis Markers. 2023; 2023:9910542.
PMID: 37091892 PMC: 10121356. DOI: 10.1155/2023/9910542.
T-Cell Responses after Rotavirus Infection or Vaccination in Children: A Systematic Review.
Laban N, Goodier M, Bosomprah S, Simuyandi M, Chisenga C, Chilyabanyama O Viruses. 2022; 14(3).
PMID: 35336866 PMC: 8951614. DOI: 10.3390/v14030459.
Vaccines for preventing rotavirus diarrhoea: vaccines in use.
Bergman H, Henschke N, Hungerford D, Pitan F, Ndwandwe D, Cunliffe N Cochrane Database Syst Rev. 2021; 11:CD008521.
PMID: 34788488 PMC: 8597890. DOI: 10.1002/14651858.CD008521.pub6.